BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has announced preliminary findings from a Phase II study with intramuscular injection of Peramivir, the Company’s product candidate for the treatmen… more →
24/7 Wall St.wrote 1 year ago: (Ack. Wrote this on Friday, and completely forget to post) Here we go – I can’t compete with … more →
wrote 3 years ago: On November 4 2009 BioCryst Pharmaceuticals Inc announced that it is to receive a regulatory milesto … more →
wrote 5 years ago: BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has announced preliminary findings from a Phase II stu … more →
wrote 5 years ago: BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has announced preliminary findings from a Phase II stu … more →